| Regulatory Story | ||||||||||||
| Go to market news section |
|
|||||||||||
|
||||||||||||
22 January 2013
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Exercise of Options
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 23,850 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 25 January 2013. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company.
The total number of shares in issue (inclusive of the above issue) is 409,866,831 Ordinary shares of 0.1p each.
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Manuel Llobet, Chief Executive Officer |
|
|
Ian Postlethwaite, Finance Director |
|
|
|
|
|
|
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson / Clare Terlouw |
|
|
|
|
|
FTI Consulting |
+44 (0) 207 831 3113 |
|
Simon Conway / Susan Stuart / Victoria Foster Mitchell |
|
This information is provided by RNS
 |
 |
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| © London Stock Exchange plc. All rights reserved |